Bellicum Pharmaceuticals Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T ® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.
No news available
Limited Time
Get premium stock ratings, research, analyst insights, and portfolio tools with a limited-time discount.
25% off Seeking Alpha Premium through July 7.
Claim 25% discountSponsored partner offer: The 25% Seeking Alpha Premium discount is available for a limited time. Terms apply.